Zepbound

News

Lilly says tirzepatide staves off diabetes in phase 3 trial

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob

News

Lilly says tirzepatide supply issues are resolving

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for startin

News

Novo Nordisk chief executive Lars Fruergaard Jørgensen

Wegovy slowdown rattles Novo Nordisk investors

Shares in Novo Nordisk have gone into reverse after it reported weaker-than-expected sales of obesity therapy Wegovy, raising concerns among investors about growing competition in the categ

News

Lilly ups spend on diabetes, obesity drug production to $9bn

Eli Lilly is determined not to be left behind when it comes to manufacturing capacity for new diabetes and obesity therapies, raising its spending on a new plant in Indian

News

Wegovy sales double, as starting restrictions start to lift

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy

News

Heart claims unlock Medicare coverage of obesity drugs

Medicare has loosened restrictions on the reimbursement of obesity drugs, thanks to clinical data showing they can improve cardiovascular outcomes, but their price could b

Lilly says tirzepatide staves off diabetes in phase 3 trial

Lilly says tirzepatide supply issues are resolving

Wegovy slowdown rattles Novo Nordisk investors

Lilly ups spend on diabetes, obesity drug production to $9bn

Wegovy sales double, as starting restrictions start to lift

Heart claims unlock Medicare coverage of obesity drugs

Setback for MSD as German court blocks Keytruda SC launch

How to meet your physicians where they are online

Zepbound

Editor's Picks